An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy.
about
Interventions for sexual dysfunction following treatments for cancerFactors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study.Patterns of treatment with PDE5 inhibitors in the clinical practice in Italy: longitudinal data from the Erectile Dysfunction Observational Study.The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension.A meta-regression analysis of treatment effect modifiers in trials with flexible-dose oral sildenafil for erectile dysfunction in broad-spectrum populations.An open-label, multicenter, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in Chinese men naïve to phosphodiesterase 5 inhibitor therapy.Tadalafil for prevention of erectile dysfunction after radiotherapy for prostate cancer: the Radiation Therapy Oncology Group [0831] randomized clinical trialPsychosexual care in prostate cancer survivorship: a systematic review.Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?An analysis of treatment preferences and sexual quality of life outcomes in female partners of Chinese men with erectile dysfunctionPatient preference and satisfaction in erectile dysfunction therapy: a comparison of the three phosphodiesterase-5 inhibitors sildenafil, vardenafil and tadalafilTadalafil once daily in the management of erectile dysfunction: patient and partner perspectivesPatients' preference in the treatment of erectile dysfunction: a critical review of the literature.Chronic PDE-5 inhibition in patients with erectile dysfunction - a treatment approach using tadalafil once-daily.ADMET considerations for phosphodiesterase-5 inhibitors.Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis.Tadalafil in the treatment of erectile dysfunction.Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction.Relationship between erectile function and sexual self-confidence: a path analytic model in men being treated with tadalafil.Large-scale questionnaire survey of erectile dysfunction drugs in Japanese men.
P2860
Q24242883-993CC396-D71D-48D5-A5E1-EED0518FE770Q31114948-71AD3CC0-4AEB-448F-BA90-13A489392D58Q33495987-7FD42732-AE95-4ED5-B60C-37ADEA300172Q33844740-04EED979-40CF-467E-BB38-23B22D2A22BDQ34524277-6DE52FC3-A1C7-4608-A5F2-DC0E6AD42B33Q34927979-AFB0E8D9-DB58-4297-BBDB-41B4DA54537BQ36345217-BB5BB315-21C0-4E33-9792-B1E9152D3E09Q36451194-2B648C14-7AA7-4A99-A9C5-5924ABA66010Q36689825-5756CF54-3A21-4C23-835A-CC17FD3BD487Q37210359-9AD11D29-615D-421F-930A-2C0CBC22EA24Q37423701-6238DC4D-6DD3-498B-9D5D-C54E57C40D75Q37423713-33FAB01E-1E86-439A-85D5-5B9F286703B2Q37824592-61D52335-066D-4F2E-9D6F-CEFC8E643CF1Q38020943-31DBD921-8627-4A1E-9ACD-3D5DC85CC7ABQ38024409-5C9A1E60-F908-47A2-96CA-1ABEFA593ECDQ39456281-F8AC2E84-50D7-48A3-B076-CC72A119CB0BQ41978073-CF29C8C2-D267-4B51-9443-4B72501E78E1Q41998659-A8C5A294-F0DC-4BA5-B886-19D9A61D9279Q42609456-5209B94E-40A3-4D63-8D90-9ECEBAFFE7E9Q55002512-785DE60D-9D1C-4FC3-9283-DE8D2B7EC62F
P2860
An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
An open-label, multicentre, ra ...... iesterase 5 inhibitor therapy.
@en
An open-label, multicentre, ra ...... iesterase 5 inhibitor therapy.
@nl
type
label
An open-label, multicentre, ra ...... iesterase 5 inhibitor therapy.
@en
An open-label, multicentre, ra ...... iesterase 5 inhibitor therapy.
@nl
prefLabel
An open-label, multicentre, ra ...... iesterase 5 inhibitor therapy.
@en
An open-label, multicentre, ra ...... iesterase 5 inhibitor therapy.
@nl
P2093
P2860
P1433
P1476
An open-label, multicentre, ra ...... iesterase 5 inhibitor therapy.
@en
P2093
Anthony Beardsworth
David Ralph
Francesco Montorsi
Ian Eardley
Margaret R Warner
Philip Kell
Vincenzo Mirone
Yanli Zhao
P2860
P304
P356
10.1111/J.1464-410X.2005.05892.X
P577
2005-12-01T00:00:00Z